BIOTECHONCOLOGY PRODUCT LINE
Oncology medicine portfolio
Oncology medicine enquiries focused on recent launches and Chinese innovative drugs for healthcare professionals and institutions.
Focused on Chinese innovation and recent launches
HUNDO’s oncology medicine portfolio supports information enquiries for healthcare professionals and institutions, with priority given to Chinese innovative oncology medicines, recent approvals, targeted therapies, immuno-oncology medicines and chemotherapy products. Indications, dosing, contraindications, supply and approval status must be checked against locally authorised product information and regulatory records.
Chinese innovative and recently approved oncology medicines
| Rilertinib Mesylate Tablets（圣瑞沙） | EGFR kinase inhibitor information for EGFR T790M-mutated NSCLC; listed in NMPA approval information in 2025. |
|---|---|
| Zorifertinib Hydrochloride Tablets（泽瑞尼） | EGFR-focused therapy information for EGFR-mutated NSCLC with CNS metastases; listed by NMPA in 2025. |
| Garsorasib Tablets（安方宁） | KRAS G12C-focused medicine information for advanced NSCLC; conditionally approved in China in 2025. |
| Envonalkib Citrate Capsules（安洛晴） | ALK-positive locally advanced or metastatic NSCLC information; listed by NMPA in 2025. |
| Golidocitinib Capsules（高瑞哲） | JAK1 inhibitor information for relapsed or refractory peripheral T-cell lymphoma; conditionally approved in China in 2025. |
| Finotonlimab Injection（安佑平） | PD-1 monoclonal antibody information, including recurrent or metastatic head and neck squamous cell carcinoma; listed by NMPA in 2025. |
| Senaparib Capsules（派舒宁） | PARP inhibitor information for maintenance treatment in ovarian, fallopian tube or primary peritoneal cancer; listed by NMPA in 2025. |
| Sunvozertinib Tablets（舒沃哲） | EGFR exon 20 insertion-mutated NSCLC information; listed by NMPA in 2023. |
| Rezivertinib Mesylate Capsules（瑞必达） | Third-generation EGFR-TKI information for EGFR T790M-mutated NSCLC; listed by NMPA in 2024. |
| Iruplinalkib Tablets（启欣可） | ALK/ROS1-related small-molecule information for ALK-positive NSCLC; listed by NMPA in 2023. |
Established oncology medicine information
| Targeted therapy and anti-angiogenesis | Osimertinib, Lenvatinib, Bevacizumab, Trastuzumab and related product information. |
|---|---|
| Immunotherapy and monoclonal antibodies | Pembrolizumab, Nivolumab, Rituximab and related documentation topics. |
| Chemotherapy and established anticancer medicines | Paclitaxel, Docetaxel, Gemcitabine, Capecitabine, Cisplatin and Oxaliplatin. |
The examples above are representative enquiry items, not a complete catalogue or a commitment to supply in any market. Specific products, strengths, registration documents and availability require case-by-case confirmation.
Compliance note
Oncology medicines are often prescription-only or otherwise strictly regulated therapeutic products. This page is an information enquiry entry for healthcare professionals, institutional customers and partners; it does not provide public online purchasing, medication recommendations, price promotion or efficacy guarantees. Indications, contraindications, warnings, approval status, importation and supply must be checked against local regulatory approvals, authorised product information and prescription requirements.
Information to include in your enquiry
- Generic name, brand name if available, and required strength.
- The country or region relevant to your enquiry.
- Your institution and the documentation, qualification or supply information you wish to verify.
Reference resources
China’s National Medical Products Administration (NMPA) publishes drug approval information. The US National Cancer Institute (NCI) provides an A-Z index of cancer drugs and introduces treatment types including chemotherapy, targeted therapy and immunotherapy. Treatment selection depends on cancer type, stage and individual circumstances and belongs with the treating team.
Read NMPA: drug approval information ↗
Read NCI: A to Z List of Cancer Drugs ↗
Read NCI: Types of Cancer Treatment ↗
Frequently asked questions
Can individuals buy oncology medicines on this website?
There is no online checkout, price promotion or public medication advice for oncology medicines. Use requires medical assessment and compliance with local prescription, registration and supply requirements.
Are all listed medicines available from stock?
The listed medicines are representative enquiry items. Specific strengths, registration status, availability and qualification documents must be confirmed with the HUNDO team.
Prepared for the HUNDO website · Updated: 2026-09-11